Top Markets
Coin of the day
Boston Scientific Corporation Boston Scientific Corporation

Boston Scientific Corporation

BSX
Rank in Stocks #210
Boston Scientific Corporation develops, manufactures, and markets medical... Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Share Price
$62.83
Market Cap
$93.23B
Change (1 day)
-9.17%
Change (1 year)
-31.36%
Country
US
Trade Boston Scientific Corporation (BSX)

Category

P/E ratio for Boston Scientific Corporation (BSX)
P/E ratio as of April 2026 TTM: 32.19
According to Boston Scientific Corporation latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 32.19. At the end of 2024 the company had a P/E ratio of 70.89.
P/E ratio history for Boston Scientific Corporation from 2000 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) 32.19 -34.18%
2025 48.91 -31.01%
2024 70.89 34.45%
2023 52.73 -44.39%
2022 94.83 63.23%
2021 58.10 -109.35%
2020 -621.10 -4,739.24%
2019 13.39 -54.16%
2018 29.21 -91.06%
2017 326.58 285.92%
2016 84.63 -182.61%
2015 -102.44 -30.52%
2014 -147.45 10.67%
2013 -133.23 6,624.20%
2012 -1.98 -110.84%
2011 18.28 -269.40%
2010 -10.79 -18.52%
2009 -13.24 132.42%
2008 -5.70 -83.69%
2007 -34.93 471.06%
2006 -6.12 -118.98%
2005 32.22 15.12%
2004 27.99 -56.60%
2003 64.49 39.54%
2002 46.22 -124.91%
2001 -185.54 -1,347.09%
2000 14.88 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
27.47 -14.67%
US
38.72 20.27%
US
24.08 -25.21%
IE
24.08 -25.21%
IE
19.12 -40.60%
DE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.